Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • b_leaguered b_leaguered Nov 30, 2012 3:35 PM Flag

    Wedbush Says Insmed Weakness Could Be Related to Theravance's FDA Panel Decision

    "05:29 PM EST, 11/29/2012 (MidnightTrader) -- Theravance (THRX) today reported that the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) has given the company a favorable response for its antibiotic VIBATIV (telavancin) for the treatment of nosocomial pneumonia due to susceptible isolates of Gram-positive microorganisms.
    In the company's meeting with the advisory committee, it received 6 (yes) votes and 9 (no) votes that the results it provided showed substantial evidence of the safety and effectiveness of VIBATIV for the requested indication; and 13 (yes) and 2 (no) votes that the results provided showed substantial evidence of the safety and effectiveness of VIBATIV for the treatment of nosocomial pneumonia when other alternatives are not suitable."
    Note: this is an injectable drug.
    If this is true, then someone must have factored in pneumonia as a potential future indication for Arikace.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wedbush Says Insmed Weakness Could Be Related to Theravance's FDA Panel Decision

      By b_leaguered.Nov 30, 2012 3:35 PM
      "05:29 PM EST, 11/29/2012 (MidnightTrader) -- Theravance (THRX) today reported that the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) has given the company a favorable response for its antibiotic VIBATIV (telavancin) for the treatment of nosocomial pneumonia due to susceptible isolates of Gram-positive microorganisms.
      In the company's meeting with the advisory committee, it received 6 (yes) votes and 9 (no) votes that the results it provided showed substantial evidence of the safety and effectiveness of VIBATIV for the requested indication; and 13 (yes) and 2 (no) votes that the results provided showed substantial evidence of the safety and effectiveness of VIBATIV for the treatment of nosocomial pneumonia when other alternatives are not suitable."
      Note: this is an injectable drug.
      If this is true, then someone must have factored in pneumonia as a potential future indication for Arikace.

    • Insmed is not mentioned in the body of the quote. Is the inference in the last sentence yours or Wedbush's?

    • At first glance of the chart, I thought it was Obama taking us over the so-called "fiscal cliff."

      Sentiment: Strong Buy

    • BL - Great Find, although I don't think it's a very good reason for an inhalation development company to fall, it is a better reason than because Terry told us iPLEX is dead!

    • Nice find, thanks.

 
INSM
11.45+0.12(+1.06%)Jul 29 4:00 PMEDT